Rivastigmine in Mild Alzheimer's Disease, FMRI Study (ADFRMI)

Kuopio University Hospital

Status: Completed

Conditions: Alzheimer' Disease

Treatments: Drug: rivastigmine

Study type: Interventional

Funder types: Other

Identifiers

NCT00627848

KUH5772749

Details and patient eligibility

About

The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated with long term treatment effect at 6 months and 12 months.

Enrollment: 20 patients

Sex: All

Ages: 55 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Probable Alzheimer's disease according to the NINCDS-ADRDA criteria
• mild disease, CDR 1
• the clinician is planning to start anticholinesterase treatment

Exclusion criteria

• cognitive impairment for other reason than Alzheimer's disease
• severe depression
• other unstable physical disease
• medal in body prevention MRI examination, claustrophobia
• cardiac pacemaker
• other significant neurologic or psychiatric disease
• contraindication for anticholinesterase treatment

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind